AI Engines For more Details: Perplexity Kagi Labs You
Prostate Cancer: Bicalutamide is classified as an antiandrogen medication. It works by blocking the action of androgens (male hormones), particularly testosterone, on the prostate gland. Prostate cancer cells often rely on androgens to grow and spread. By blocking the effects of androgens, bicalutamide helps slow down the progression of prostate cancer, relieve symptoms, and improve quality of life in patients with advanced or metastatic prostate cancer.
Androgen Deprivation Therapy (ADT): Bicalutamide is commonly used as part of androgen deprivation therapy (ADT) in combination with a luteinizing hormone-releasing hormone (LHRH) agonist or antagonist. ADT aims to reduce the levels of circulating testosterone in the body, as testosterone fuels the growth of prostate cancer cells. Bicalutamide blocks the androgen receptors in prostate cancer cells, preventing them from receiving signals to grow in the absence of testosterone.
Metastatic Prostate Cancer: Bicalutamide is indicated for the treatment of metastatic prostate cancer, where the cancer has spread beyond the prostate gland to other parts of the body, such as the bones or lymph nodes. It helps control the growth and spread of cancer cells in metastatic sites and may alleviate symptoms associated with advanced prostate cancer, such as bone pain or urinary obstruction.
Localized Prostate Cancer: Bicalutamide may also be used as part of combined androgen blockade (CAB) therapy in the treatment of localized prostate cancer, where the cancer is confined to the prostate gland and has not spread to other organs. CAB combines an LHRH agonist or antagonist with an antiandrogen like bicalutamide to achieve maximal suppression of androgens and improve treatment outcomes.
Adverse Effects: Common side effects associated with bicalutamide therapy include hot flashes, gynecomastia (enlargement of breast tissue in men), decreased libido, erectile dysfunction, fatigue, nausea, and liver function abnormalities. Rare but serious side effects may include allergic reactions, liver toxicity, lung inflammation, and cardiovascular events. Patients should be monitored regularly for side effects during treatment.
Hormone-sensitive Prostate Cancer: Bicalutamide is most effective in hormone-sensitive prostate cancer, where the cancer cells are still responsive to hormonal manipulation. Over time, some prostate cancers may become resistant to hormonal therapies like bicalutamide, leading to disease progression. In such cases, alternative treatment options may be considered, such as chemotherapy or second-line hormonal therapies.
Duration of Treatment: The duration of bicalutamide treatment varies depending on the stage and aggressiveness of prostate cancer, as well as individual patient factors. Treatment may be given for a few months to several years, and decisions regarding the continuation or discontinuation of therapy are typically made based on disease response, tolerance to treatment, and the presence of side effects.
Contraindications: Bicalutamide is contraindicated in individuals with known hypersensitivity to the medication or any of its components. It should not be used in women or children, as it can cause fetal harm during pregnancy and may affect male sexual development in children.
Follow-up Care: Patients receiving bicalutamide therapy require regular monitoring by their healthcare providers, including clinical evaluations, blood tests (including liver function tests), and imaging studies to assess treatment response and detect any potential complications or disease progression.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
| ADHD | 0.9 | 0.9 | |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 0.5 | 0.5 | |
| Allergies | 0.1 | 0.3 | -2 |
| Allergy to milk products | 0.1 | 0.4 | -3 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 1.4 | 0.5 | 1.8 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.2 | 0.2 | |
| Ankylosing spondylitis | 1.5 | 0.4 | 2.75 |
| Anorexia Nervosa | 0.4 | 0.1 | 3 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.2 | 1 |
| Asthma | 0.1 | -0.1 | |
| Atherosclerosis | 0.3 | 0.1 | 2 |
| Atrial fibrillation | 0.7 | 1 | -0.43 |
| Autism | 1.4 | 1.3 | 0.08 |
| Barrett esophagus cancer | 0.3 | 0.2 | 0.5 |
| Bipolar Disorder | 0.7 | 0.7 | |
| Brain Trauma | 0.1 | -0.1 | |
| Carcinoma | 0.9 | 0.5 | 0.8 |
| Celiac Disease | 0.3 | 0.7 | -1.33 |
| Cerebral Palsy | 0.2 | 0.1 | 1 |
| Chronic Fatigue Syndrome | 0.6 | 2.1 | -2.5 |
| Chronic Kidney Disease | 0.5 | 0.5 | |
| Chronic Lyme | 0.1 | -0.1 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 1.3 | |
| Chronic Urticaria (Hives) | 0.2 | 0.5 | -1.5 |
| Coagulation / Micro clot triggering bacteria | 0.6 | 0.2 | 2 |
| Colorectal Cancer | 2.2 | 2.2 | |
| Constipation | 0.1 | 0.1 | |
| COVID-19 | 2.1 | 1.5 | 0.4 |
| Crohn's Disease | 2 | 1 | 1 |
| cystic fibrosis | 0.1 | -0.1 | |
| deep vein thrombosis | 0.2 | -0.2 | |
| Depression | 3.1 | 1.7 | 0.82 |
| Dermatomyositis | 0.2 | 0.2 | |
| Eczema | 0.8 | -0.8 | |
| Endometriosis | 0.7 | 0 | 0 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | |
| Epilepsy | 0.7 | 1.3 | -0.86 |
| Fibromyalgia | 1.2 | 0.5 | 1.4 |
| Functional constipation / chronic idiopathic constipation | 0.6 | 0.5 | 0.2 |
| gallstone disease (gsd) | 0.4 | 0.3 | 0.33 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.2 | 1.5 |
| Generalized anxiety disorder | 0.3 | 0.1 | 2 |
| Glioblastoma | 0.2 | -0.2 | |
| Graves' disease | 0.5 | 0.5 | |
| Halitosis | 0.4 | 0.2 | 1 |
| Hashimoto's thyroiditis | 0.1 | 0.2 | -1 |
| Hidradenitis Suppurativa | 0.7 | 0.7 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.1 | 0.1 | |
| hypercholesterolemia (High Cholesterol) | 0 | 0 | |
| hyperglycemia | 0.5 | -0.5 | |
| hypersomnia | 0.2 | -0.2 | |
| hypertension (High Blood Pressure | 0.7 | 0.6 | 0.17 |
| Hypoxia | 0.5 | 0.5 | |
| IgA nephropathy (IgAN) | 0.6 | -0.6 | |
| Inflammatory Bowel Disease | 0.9 | 1.5 | -0.67 |
| Insomnia | 0.3 | 0.1 | 2 |
| Intelligence | 0.1 | 0.3 | -2 |
| Intracranial aneurysms | 0.5 | 0.5 | |
| Irritable Bowel Syndrome | 0.2 | 0.6 | -2 |
| Liver Cirrhosis | 1.2 | 0.4 | 2 |
| Long COVID | 1.2 | 1.2 | 0 |
| ME/CFS with IBS | 0.2 | 0.1 | 1 |
| ME/CFS without IBS | 0.3 | 1 | -2.33 |
| Metabolic Syndrome | 1.4 | 1.5 | -0.07 |
| Mood Disorders | 3.2 | 1.7 | 0.88 |
| multiple chemical sensitivity [MCS] | 0.7 | 0.7 | |
| Multiple Sclerosis | 1.8 | 2.1 | -0.17 |
| Multiple system atrophy (MSA) | 0.2 | 0.2 | |
| Neuropathy (all types) | 0.2 | 0.2 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0 | 0 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.5 | 0.1 | 4 |
| Obesity | 0.9 | 1.6 | -0.78 |
| obsessive-compulsive disorder | 0.9 | 0.4 | 1.25 |
| Osteoarthritis | 0.3 | 0.3 | |
| Osteoporosis | 0.1 | 0.1 | 0 |
| pancreatic cancer | 0.2 | 0.2 | |
| Parkinson's Disease | 0.8 | 0.7 | 0.14 |
| Polycystic ovary syndrome | 0.5 | 0 | 0 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.1 | -0.1 | |
| Psoriasis | 0.3 | 1.8 | -5 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.9 | 0.6 | 2.17 |
| Schizophrenia | 0.8 | 0.8 | |
| scoliosis | 0.2 | -0.2 | |
| Sjögren syndrome | 1 | 0.6 | 0.67 |
| Sleep Apnea | 0.3 | 0.1 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0.5 | |
| Stress / posttraumatic stress disorder | 0.8 | 0.1 | 7 |
| Systemic Lupus Erythematosus | 1.4 | 0 | 0 |
| Tic Disorder | 0 | 0.3 | 0 |
| Tourette syndrome | 0.1 | -0.1 | |
| Type 1 Diabetes | 0.4 | 0.2 | 1 |
| Type 2 Diabetes | 1.4 | 1.4 | 0 |
| Ulcerative colitis | 0.4 | 1.1 | -1.75 |
| Unhealthy Ageing | 1.6 | 0 | 0 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.